Zevra Therapeutics (ZVRA) Total Non-Current Liabilities (2014 - 2026)

Zevra Therapeutics' Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $70.9 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 38.61% year-over-year to $70.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.9 million (down 38.61% YoY) and the FY2025 annual result came in at $123.0 million, up 1.98% from the prior year.
• Total Non-Current Liabilities was $70.9 million for Q1 2026 at Zevra Therapeutics, down from $123.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $135.7 million in Q2 2025 and bottomed at -$8.5 million in Q1 2022.
• A 5-year average of $81.8 million and a median of $94.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Peak annual rise in Total Non-Current Liabilities reached 593.97% in 2022, while the deepest fall reached 237.36% in 2022.
• Zevra Therapeutics' Total Non-Current Liabilities stood at $40.2 million in 2022, then jumped by 134.76% to $94.4 million in 2023, then advanced by 27.86% to $120.7 million in 2024, then advanced by 1.98% to $123.0 million in 2025, then sank by 42.37% to $70.9 million in 2026.
• Business Quant data shows ZVRA's Total Non-Current Liabilities at $70.9 million in Q1 2026, $123.0 million in Q4 2025, and $133.0 million in Q3 2025.